Back

A synthetic bispecific antibody capable of neutralizing SARS-CoV-2 Delta and Omicron

Yuan, T. Z.; Lucas, C.; Monteiro, V. S.; Iwasaki, A.; Yang, M. L.; Nepita, H. F.; Lujan Hernandez, A. G.; Taft, J. M.; Frei, L.; Reddy, S. T.; Weber, C.; Malobisky, K. P.; Mesquita, R.; Sato, A.

2022-01-04 immunology
10.1101/2022.01.04.474803 bioRxiv
Show abstract

Bispecific antibodies have emerged as a promising strategy for curtailing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune escape. This brief report highlights RBT-0813 (also known as TB493-04), a synthetic, humanized, receptor-binding domain (RBD)-targeted bispecific antibody that retains picomolar affinity to the Spike (S) trimers of all major variants of concern and neutralizes both SARS-CoV-2 Delta and Omicron in vitro.

Matching journals

The top 10 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.